[Taking of position in relationship to the protocol of the current treatment of thyroid nodules and differentiated thyroid cancer].
Gómez Sáez
José Manuel
JM
Servicio de Endocrinología y Nutrición, Hospital de Bellvitge, Barcelona, España. jmgs@bellvitgehospital.cat
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D044963:Biopsy, Fine-Needle; D002277:Carcinoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002648:Child; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D019468:Disease Management; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy; D009367:Neoplasm Staging; D011300:Preoperative Care; D011994:Recombinant Proteins; D018570:Risk Assessment; D013030:Spain; D013954:Thyroglobulin / Q000097:blood / Q000276:immunology; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D016606:Thyroid Nodule / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods; D013972:Thyrotropin / Q000097:blood
D000970:Antineoplastic Agents; D001323:Autoantibodies; D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; C006606:anti-thyroglobulin; D013972:Thyrotropin; D013954:Thyroglobulin